Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

PURPOSE: A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose and recommended phase 2 dose of efatutazone and paclitaxel in anaplastic thyroid cancer. EXPERIMENTAL DESIGN: Patients received efatutazone (0.15, 0.3, or 0.5 mg) orally twice daily an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Smallridge, R. C., Copland, J. A., Brose, M. S, Wadsworth, J. T., Houvras, Y., Menefee, M. E., Bible, K. C., Shah, M. H., Gramza, A. W., Klopper, J. P., Marlow, L. A., Heckman, M. G., Von Roemeling, R.
Formato: Artigo
Idioma:Inglês
Publicado: Endocrine Society 2013
Assuntos:
Endocrine Care
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3667260/
https://ncbi.nlm.nih.gov/pubmed/23589525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-1106
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares